CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Anidulafungindrug
Likely dose
Anidulafungin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01307930
NCT01307930Phase 4Completed
CompareCT.gov

Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers

Texas Tech University Health Sciences Center·interventional·Posted Mar 3, 2011·Updated Jan 9, 2019

In Brief

A Phase 4 clinical trial evaluating Anidulafungin for Obesity and Mycoses. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will find how weight affects the dosing of a drug called anidulafungin. Currently, the amount of anidulafungin a patient receives is the same regardless of the patient's weight. BMI groups were for enrollment purposes only and not used for ordinal data analysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Mycoses
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR), University of Texas Southwestern Medical Center

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 3, 2011
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.3 years ago

Interventions

Anidulafungindrug

Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)